Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
Department of Prevention and Healthcare, Fujian Medical University Union Hospital, Fuzhou, China
Research Article
Efficacy and Safety of Transarterial Chemoembolization Combined with First-Line Tyrosine Kinase Inhibitors and Programmed Death-1 Inhibitors for Progressed Hepatocellular Carcinoma
Author(s): Wei-Zhu Yang*, Long-Wang Lin, Yu-Xia Nian, Rong Chen, Kun Ke, Jun-Qing Lin and Ning Huang*
Background: After the failure of Transarterial Chemoembolization (TACE) combined with first-line Tyrosine Kinase Inhibitor (TKI) therapy, the optimal treatment for Hepatocellular Carcinoma (HCC) patients who have progressed is unclear. The study was conducted to investigate the safety and efficacy of subsequent Programmed Death-1 (PD-1) inhibitor combinations compared with switching to the subsequent regorafenib.
Methods: This retrospective study examined the data of patients with HCC who failed TACE combined with first-line TKI therapy. Progression-Free Survival (PFS) and Overall Survival (OS) were assessed as primary study outcomes. An analysis of survival curves using Kaplan-Meier method was conducted and log-rank tests were used to measure differences.
Results: We enrolled a final total of 113 patients, includi.. View More»
DOI:
10.35248/2471-9552.24.10.259